TY - JOUR
T1 - Proposed Intranasal Route for Drug Administration in the Management of Central Nervous System Manifestations of COVID-19
AU - Siddiqui, Ruqaiyyah
AU - Khan, Naveed Ahmed
PY - 2020/6/3
Y1 - 2020/6/3
N2 - There is mounting evidence of the central nervous system manifestations associated with COVID-19, particularly in severe cases. Up to 25% of COVID-19 cases exhibit neurological manifestations associated with COVID-19. In view of the devastating nature of the disease due to severe acute respiratory syndrome coronavirus 2, here we debate intranasal drug delivery, in addition to intravenous delivery, as a therapeutic strategy in the management of COVID-19 cases with central nervous system involvement.
AB - There is mounting evidence of the central nervous system manifestations associated with COVID-19, particularly in severe cases. Up to 25% of COVID-19 cases exhibit neurological manifestations associated with COVID-19. In view of the devastating nature of the disease due to severe acute respiratory syndrome coronavirus 2, here we debate intranasal drug delivery, in addition to intravenous delivery, as a therapeutic strategy in the management of COVID-19 cases with central nervous system involvement.
UR - http://www.scopus.com/inward/record.url?eid=2-s2.0-85085748242&partnerID=MN8TOARS
U2 - 10.1021/acschemneuro.0c00288
DO - 10.1021/acschemneuro.0c00288
M3 - Article
SN - 1948-7193
VL - 11
SP - 1523
EP - 1524
JO - ACS Chemical Neuroscience
JF - ACS Chemical Neuroscience
IS - 11
ER -